China Evidence-Based Manufacturers & Supplier

Conventional extract suppliers focus almost entirely on biomass reduction (e.g., 10:1 or 20:1 concentration ratios) without standardizing for specific bioactive molecular constituents, ignoring batch-to-batch chemical deviation, physiological bioavailability, or clinical substantiation. In contrast, an evidence-based manufacturer like MedGence operates as a combined CRO/CDMO. We employ quantitative High-Performance Thin-Layer Chromatography (HPTLC) fingerprinting, LC-MS/MS, and GC-FID to map specific active chemical families. Furthermore, our products are backed by empirical preclinical in vitro cellular assays, animal toxicity and efficacy studies, and human clinical trials, creating a defensible regulatory package that protects brand owners from regulatory injunctions.

Yes. One of our primary organizational strengths is eliminating the knowledge friction and operational risks that arise when scientific research is separated from commercial manufacturing. Our Changsha scientific research team identifies target active molecules, determines the ideal harvest season and geographical origin, develops validated analytical assays, executes safety and efficacy studies, and models pilot-scale extraction. When parameters are locked, our directly supervised commercial manufacturing plants take over full-scale cGMP production. This closed-loop continuity guarantees that the critical quality attributes verified in the laboratory are faithfully preserved across multi-ton commercial batches.

Quality assurance begins with raw material verification and continues through final release testing. Depending on the botanical species, we use HPTLC for visual identification and fingerprint comparison against pharmacopeial reference standards. We deploy high-performance liquid chromatography with diode-array detection or tandem mass spectrometry (HPLC-DAD/MS) for quantitative active assaying, gas chromatography (GC-MS/FID) for volatile constituents and pesticide screening, inductively coupled plasma mass spectrometry (ICP-MS) for heavy metal trace quantification, and PCR-based DNA barcoding to rule out adulteration with morphologically similar related plant species.

We operate strictly under an entrusted research and contract development model governed by robust, internationally recognized Non-Disclosure Agreements (NDAs). MedGence treats client formula recipes, process parameters, and assay blueprints with enterprise-grade security protocols. Project documentation is managed within access-restricted data silos, physical manufacturing runs are insulated using dedicated processing trains, and personnel operate under strict legal non-compete agreements. We have maintained an unblemished IP protection record across 14+ years of collaboration with over 100 domestic and international pharmaceutical conglomerates.

To support FDA NDI notifications, GRAS submissions, or international botanical drug dossiers, our preclinical laboratory conducts full OECD- and GLP-compliant toxicological testing. This includes Acute Oral Toxicity (determination of LD50 values), 14-day and 28-day range-finding studies, 90-day subchronic toxicity evaluations in rodents, and complete genetic toxicology battering: Bacterial Reverse Mutation (Ames Test), in vitro Mammalian Chromosome Aberration, and in vivo Rodent Micronucleus Assays. For target claims substantiation, we execute bespoke disease-model animal studies (metabolic syndrome, anti-inflammatory pathways, cognitive support, hepatoprotection).

Yes. We design and manage human clinical protocols tailored to the target regulatory pathway. For nutraceutical and cosmetic clients, we coordinate small-to-medium cohort, randomized, double-blind, placebo-controlled human efficacy studies (typically 30 to 120 subjects) to generate statistically significant data substantiating brand marketing and label claims. For pharmaceutical clients seeking formal botanical drug registration, our clinical team manages full Good Clinical Practice (GCP) Phase I pharmacokinetic/safety studies through Phase II, III, and IV multicenter clinical investigations in collaboration with accredited university hospital networks across China.

Our intermediate supply covers concentrated liquid infusions, purified high-potency dry extracts, hydro-alcoholic pastes, volatile steam-distilled essential oils, and standardized single-herb active isolates. For finished turnkey products, our CDMO facilities offer hard gelatin and vegetarian HPMC capsules, softgels, high-speed rotary compressed tablets (including enteric-coated and chewable options), water-soluble micro-granules, sachet powders, and sterile oral liquid ampoules packaged ready for commercial retail distribution.

Secondary metabolites are adaptive biochemicals produced by plants in response to specific climatic stressors, soil chemistry, elevation, and sunlight exposure. For example, our research indicates that saponin and flavonoid concentrations in plants such as *Panax notoginseng* or *Epimedium brevicornu* can fluctuate by more than 300% depending on whether harvesting occurs in early spring versus late autumn, or if cultivated in Yunnan versus northern Sichuan. By systematically evaluating botanical biomass across geographic origins and harvest windows, we assist clients in locking in supply agreements that maximize active yield per dollar expended, eliminating excessive processing costs.